Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine compounds
AssigneeThe Regents of the University of California
InventorsRanjan Dohil, Patrice Rioux
Life of this patent
Estimating the term…
Abstract
The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine or cystamine compositions. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Claims27
A method of treating a subject comprising:
- measuring one or more markers of liver function in the blood, plasma or serum of the subject;
- measuring resistin, adiponectin and/or cytokeratin 18 levels in the blood, plasma or serum of the subject;
- determining if the subject's BMI is above the 97th percentile for the subject's age;
- determining if the subject has lobular inflammation or portal inflammation;
- identifying a subject with (i) liver function and resistin, adiponectin and/or cytokeratin 18 levels characteristic of a fatty liver disease, and (ii) lobular inflammation;
- and
- administering a therapeutically effective amount of a cysteamine salt or cystamine salt composition to the patient to obtain a plasma level of about 10-80 μmol of cysteamine in the plasma.
A method of treating a patient having Non-alcoholic steatohepatitis (NASH) and having lobular inflammation with little to no portal inflammation with a cysteamine or cystamine composition.
Dependencies are inferred from the claim text.